Regulatory approval

Published by the Health Service Executive. Approved

Pertuzumab/ trastuzumab (Phesgo) is indicated in combination with DOCEtaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti- HER2 therapy or chemotherapy for their metastatic disease.

This is written in the approval document.

Reimbursement

Incomplete Reimbursement

Pertuzumab / Trastuzumab (Phesgo) - ODMS 2022-12-20; Docetaxel - N/A

Citation

Pertuzumab/Trastuzumab (Phesgo) and DOCEtaxel Therapy - 21 day cycle, 2024, version number 4, NCCP National SACT Regimen, NCCP, viewed 02/08/2026, https://healthservice.hse.ie/documents/6419/796_v4_PertuzumabTrasDoc_Phesgo.pdf

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HSE (1)	HER2-positive	Invasive Breast Carcinoma	Docetaxel, Pertuzumab, Trastuzumab